Concepedia

Wilson B. Knight

WB

Statistics

Publications

31

Citations

2.6K

H-Index

24

Active since

1981

Affiliations

Research Triangle Park Foundation(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

GlaxoSmithKline (United States)

University of Wisconsin–Madison

University of Maryland, College Park

Wilson B. Knight is an author at Research Triangle Park Foundation specializing in enzymology, biochemistry, and life sciences.

Publications per year

1981–2003

31

Publications

31

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 738 citations

, , +17

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

, , +15

SH2- and SH3-mediated Interactions between Focal Adhesion Kinase and Src

Jeffrey W. Thomas, Byron Ellis, Renee J. Boerner et al. · Journal of Biological Chemistry · 1998 · 252 citations · Full text

, , +17

Characterization of pp60c-src Tyrosine Kinase Activities Using a Continuous Assay: Autoactivation of the Enzyme Is an Intermolecular Autophosphorylation Process

S. Barker, Daniel B. Kassel, D. Weigl et al. · Biochemistry · 1995 · 193 citations

, , +11

Correlation of the Phosphorylation States of pp60<sup>c-</sup><i><sup>src</sup></i> with Tyrosine Kinase Activity:  The Intramolecular pY530−SH2 Complex Retains Significant Activity If Y419 Is Phosphorylated

Renee J. Boerner, Daniel B. Kassel, S. Barker et al. · Biochemistry · 1996 · 96 citations

, , +13

1–5 of 31